How does it happen
Most common causative infection
Campylobacter jejuni, CMV, EBV
What is the main component for diagnosis ?
clinical
ascending weakness and non-length dependent sensory symptoms
Either intravenous immunoglobulin (IVIG) or plasma exchange
The most common form of GBS in North America and Europe
Acute inflammatory demyelinating polyradiculoneuropathy (AIDP)
How do you pronounce Guillain-Barré?
ghee-yan bar-ray
What structures are damaged?
Nerve insulation (myelin) and sometimes even the covered conducting part of the nerve (axon) is damaged
CSF finding? we want THAT specific term
albuminocytologic dissociation
When is patient not indicated for hospitalization?
able to walk unaided for more than 5 m and who are stable
A severe variant of GBS that is more common in Asia, Central America, and South America
Acute motor-sensory axonal neuropathy (AMSAN)
What vaccination led to increased GBS
In 1976, flu vaccination against the influenza A/H1N1 antigen led to a well-documented, increased incidence of cases of GBS
What type of antibodies are formed?
Ganglioside antibodies
When to do EMG?
electrodiagnostic studies should be undertaken at 10 to 14 days after symptom onset due to the time for Wallerian degeneration of sensory and motor nerve fibers
When is tx most beneficial?
within 7 days after disease onset
Acute brainstem dysfunction variant
Bickerstaff brainstem encephalitis
Percentage of patients dying of GBS
Less than 2% of people die from GBS
Miller-fisher antibody
anti-GQ1B
MRI findings
Enhancement of the nerve roots, indicating a breakdown of the blood-nerve barrier due to inflammation
What treatment is preferred for pediatrics
IVIG
Rarest known variant of GBS
Acute Panautonomic Neuropathy
In 1859, is credited with the first reported case of what later came to be known as the GBS.
Octave Landry
Where do Anti-GD1a antibodies bind ?
paranodal myelin, nodes of Ranvier, and neuromuscular junction
GBS nadir
4 weeks
IVIG adminitration
0.4 g/kg bodyweight per day for five consecutive days
Patients initially diagnosed with GBS who have three or more periods with clinical deterioration, or a new deterioration after 8 weeks from onset of weakness
Acute onset CIDP
Third author of GBS paper in 1916
André Strohl